Smoking Cessation: The Single Most Powerful Thing You Can Do for Your Heart

I have seen a lot of patients try to quit smoking. Some succeeded on the first attempt. Most did not. What I have learned from those encounters, and from the cardiovascular outcomes literature, is that quitting smoking is the single highest-impact intervention available to anyone with a heart. No statin, no blood pressure medication, no bypass operation delivers the same magnitude of risk reduction as stopping tobacco. If you are reading this as a smoker, or as the family member of one, I want to give you a clear-eyed picture of what smoking does to the cardiovascular system, what the evidence says about the best ways to quit, and what recovery actually looks like after the last cigarette.

What Smoking Does to the Cardiovascular System

Cigarette smoke contains roughly 7,000 chemicals, and dozens of them have direct cardiovascular toxicity. The three that do the most damage are nicotine, carbon monoxide, and oxidizing particulate matter. Nicotine raises heart rate and blood pressure through sympathetic nervous system activation. Carbon monoxide binds hemoglobin more than 200 times more tightly than oxygen, reducing the amount of oxygen the blood can deliver to tissues including the heart muscle itself. Oxidizing particulates damage the endothelium, the thin cellular lining of blood vessels that regulates vascular tone, inflammation, and clotting.

The cumulative effect is accelerated atherosclerosis, meaning smokers develop coronary artery plaque earlier and more aggressively than non-smokers. They also form clots more readily because smoking increases platelet reactivity and fibrinogen levels. A 30-year-old smoker has a vascular age closer to 40. By the time they reach their 50s, many have coronary disease that would otherwise not appear until their 70s or later.

Smoking is responsible for about one in four cardiovascular deaths globally. It nearly triples the risk of heart attack (odds ratio roughly 2.9 in pooled analyses), increases the risk of sudden cardiac death about 2.5-fold, and raises the risk of abdominal aortic aneurysm roughly five-fold. The risk scales with how many cigarettes per day and how many years of smoking, but there is no safe level. Smoking just one cigarette per day carries roughly half the coronary heart disease risk of a 20-cigarette-per-day habit, far more than a linear dose-response would predict.

What Happens After You Quit

The cardiovascular benefit of quitting starts within hours and compounds for decades. Within 20 minutes of the last cigarette, heart rate and blood pressure begin to fall. Within 12 hours, carbon monoxide levels in the blood normalize. Within two to three weeks, circulation and lung function start measurably improving. Within one year, coronary heart disease risk drops by about half compared to a continuing smoker. Within 5 to 15 years, stroke risk is nearly eliminated. For a light smoker, heart attack risk approaches the never-smoker population within 10 to 15 years; for a heavy smoker with 20 or more pack-years of exposure, full normalization of coronary risk can take 20 to 25 years of sustained cessation. The benefit continues to accumulate the longer you stay off tobacco.

For patients who already have coronary disease, the benefit is even more striking. The 2022 Cochrane review of smoking cessation after cardiovascular events found a 39 percent reduction in cardiovascular mortality (hazard ratio 0.61) and a 43 percent reduction in major adverse cardiovascular events (hazard ratio 0.57) among quitters compared to those who continued smoking. That is a larger mortality benefit than any medication we prescribe after a heart attack, including aspirin, statins, and beta-blockers. Stopping smoking is the single intervention I push hardest on every one of my post-MI patients for exactly this reason.

Why Quitting Is So Hard

Nicotine is one of the most addictive substances known to medicine, with dependence potential similar to heroin or cocaine. It binds nicotinic acetylcholine receptors in the brain and triggers dopamine release in the nucleus accumbens, the same reward pathway activated by other addictive drugs. With repeated exposure, receptor density changes and the brain becomes physiologically dependent. Within a few hours of the last cigarette, withdrawal begins — irritability, anxiety, difficulty concentrating, increased appetite, low mood, and intense craving.

On top of the pharmacology, smoking is deeply embedded in behavior. People smoke with their morning coffee, after meals, during stressful moments, with certain friends, at certain times of day. Those environmental cues continue to trigger craving long after the nicotine itself has cleared. This is why willpower alone rarely works for long-term cessation. The relapse rate for unassisted quit attempts is about 95 percent. With a structured approach combining medication and behavioral support, one-year success rates triple or quadruple.

The Evidence-Based Toolkit

There are three FDA-approved medication categories for smoking cessation, and the data strongly support using them. The 2023 Cochrane network meta-analysis, which pooled 319 randomized trials and more than 157,000 participants, found that varenicline and combination nicotine replacement approximately double placebo quit rates (odds ratios 2.33 and 1.93 respectively), while bupropion and single-form NRT increase quit rates by roughly 40 percent. Combinations and counseling push the numbers higher still.

Nicotine Replacement Therapy

Nicotine replacement therapy, or NRT, delivers nicotine without the 7,000 other combustion byproducts. The patch provides steady background nicotine to blunt withdrawal. Short-acting forms — gum, lozenge, inhaler, nasal spray — handle breakthrough cravings. The most effective NRT strategy is combination therapy: a long-acting patch plus a short-acting rescue form. Combination NRT produces quit rates comparable to varenicline and substantially better than the patch alone. NRT is safe in patients with stable cardiovascular disease, including those who have had a heart attack, and the cardiovascular risk of continued smoking vastly exceeds any risk of NRT.

Varenicline (Chantix)

Varenicline is a partial agonist at the α4β2 nicotinic receptor. It provides enough stimulation to reduce withdrawal while blocking the receptor from full activation if the patient does smoke, which blunts the pleasure of a relapse cigarette. In the EAGLES trial, biochemically confirmed continuous abstinence at weeks 9 through 24 was 21.8 percent with varenicline versus 16.2 percent with bupropion, 15.7 percent with nicotine patch, and 9.4 percent with placebo. EAGLES also showed that varenicline does not cause excess neuropsychiatric adverse events compared to placebo, and on the strength of those data the FDA removed varenicline's black box warning for psychiatric events in 2016. In the EVITA trial, which randomized patients hospitalized with an acute coronary syndrome, varenicline increased 52-week point-prevalence abstinence from 29 percent to 40 percent with no excess in major cardiovascular events. Nausea is the most common side effect and usually improves after the first few weeks. Current AHA/ACC guidelines list varenicline or combination NRT as first-line pharmacotherapy for smokers with stable cardiovascular disease.

Bupropion

Bupropion is an atypical antidepressant that also reduces nicotine craving and withdrawal. It is less effective than varenicline or combination NRT but is a reasonable choice for patients who also have depression, who cannot tolerate NRT, or who prefer an oral medication. It should be avoided in patients with seizure disorders or active eating disorders.

Behavioral Support

Medication alone works, but medication plus counseling works better. Even brief physician counseling improves quit rates. Quitline counseling is free in every state in the US and delivers meaningful benefit. Text-message programs and mobile apps like Smokefree.gov have randomized evidence behind them. The National Cancer Institute quitline (1-800-QUIT-NOW) is the easiest entry point for most patients.

What About E-Cigarettes?

E-cigarettes are a complicated topic. On one hand, randomized trials and the 2025 Cochrane living systematic review now show that e-cigarettes increase quit rates by about 55 percent compared to NRT (relative risk 1.55), with Hajek's 2019 NEJM trial reporting 18 percent one-year abstinence on e-cigarettes versus 9.9 percent on NRT. On the other hand, e-cigarettes are not FDA-approved for smoking cessation, long-term cardiovascular safety data are limited, and vaping carries its own cardiovascular risks including elevated blood pressure, endothelial dysfunction, platelet activation, and in some observational studies an increased rate of chest pain and arrhythmias. The most concerning pattern is dual use, where patients smoke and vape at the same time — pooled data show dual users have roughly 36 percent higher cardiovascular disease risk than exclusive combustible smokers (odds ratio 1.36). Adding vaping to smoking makes the cardiovascular picture worse, not better.

My approach is to steer patients toward FDA-approved therapies first. If those fail repeatedly and a patient is motivated to try switching completely to e-cigarettes as a harm-reduction bridge, I discuss the tradeoffs honestly and set a timeline for eventually tapering off the vape as well. Under no circumstance do I recommend starting e-cigarette use for someone who is not already a combustible smoker.

The Weight Gain Question

About 80 percent of people who quit smoking gain some weight, typically 7 to 13 pounds in the first year. Nicotine suppresses appetite and raises metabolic rate, and both effects reverse after quitting. Some patients refuse to quit for this reason, which is a mistake — and it is worth understanding exactly how much of a mistake. The 2018 New England Journal of Medicine analysis by Hu and colleagues, drawing on three large US cohorts, found something unexpected: cardiovascular mortality reduction was actually largest among quitters who gained the most weight. Compared to continued smokers, quitters who gained 5 to 10 kilograms of body weight had a 75 percent lower risk of cardiovascular death (hazard ratio 0.25), while quitters who gained no weight had a 31 percent lower risk (hazard ratio 0.69). Post-cessation weight gain does not merely fail to erase the benefit of quitting — it is associated with a larger survival benefit, not a smaller one.

For patients who are already overweight or diabetic, I often layer smoking cessation with structured nutrition support and sometimes pharmacotherapy for weight management. The GLP-1 receptor agonists are a useful tool here because they reliably prevent post-cessation weight gain — in a 2023 randomized trial, dulaglutide produced about 3 kilograms less weight gain than placebo when added to varenicline and counseling. GLP-1 agonists do not appear to improve abstinence rates themselves, but they do address one of the most common patient-stated reasons for avoiding cessation, and they carry their own independent cardiovascular benefit.

When to Start

The best day to start is today. The second-best day is tomorrow. Patients often want to wait for the "right time" — after a vacation, after a stressful work project, after the holidays. The right time never comes. What works is setting a specific quit date within the next two weeks, starting medication five to seven days before that date, removing cigarettes and lighters from the home and car, telling family and friends, and planning for the first hard week with specific strategies for coffee, meals, driving, and social situations.

Relapse is not failure. The average successful quitter makes between seven and 30 attempts before achieving lasting cessation. Each attempt teaches something about what triggers relapse and what strategies help. What matters is that you keep trying. Jha and colleagues, working with more than 200,000 adults in the US National Health Interview Survey, found that quitting before age 40 eliminates roughly 90 percent of the excess death risk from smoking. Quitting at age 45 adds roughly 6 years of life expectancy; quitting at age 65 still adds about 2 years. The benefit is larger the earlier it happens, but the curve is not a cliff — even cessation after 65 buys meaningful time.

What This Means for You

If you smoke and you want to stop, ask your doctor about varenicline or combination NRT, call the quitline, pick a date within two weeks, and commit to the first hard week. If you have coronary disease, prior heart attack, heart failure, or peripheral artery disease, the urgency is higher because your baseline risk is higher, but the relative benefit of quitting is also the largest.

If your partner, parent, or child smokes and you want to help them quit, know that pressure and shame are not effective. What helps is making it easier for them to succeed when they are ready — offering to attend the appointment where they get medication, removing smoking from the home, not smoking in their presence if you smoke yourself, and celebrating every quit attempt whether or not it sticks. Most smokers want to quit. Most will die from smoking if they do not. That is the clearest risk-benefit calculation in preventive cardiology.

References

1. US Surgeon General. The Health Consequences of Smoking — 50 Years of Progress. Atlanta, GA: US Department of Health and Human Services; 2014.

2. Wu AD, Lindson N, Hartmann-Boyce J, et al. Smoking cessation for secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2022.

3. Hackshaw A, Morris JK, Boniface S, Tang JL, Milenkovic D. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies. BMJ. 2018;360:j5855.

4. Ding N, Sang Y, Chen J, et al. Cigarette smoking, smoking cessation, and long-term risk of 3 major atherosclerotic diseases. J Am Coll Cardiol. 2019.

5. Lindson N, Theodoulou A, Ordóñez-Mena JM, et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses. Cochrane Database Syst Rev. 2023.

6. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387:2507-2520.

7. Benowitz NL, Pipe A, West R, et al. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial. JAMA Intern Med. 2018.

8. Eisenberg MJ, Windle SB, Roy N, et al. Varenicline for smoking cessation in hospitalized patients with acute coronary syndrome (EVITA). Circulation. 2016;133:21-30.

9. Barua RS, Rigotti NA, Benowitz NL, et al. 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment. J Am Coll Cardiol. 2018.

10. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease. J Am Coll Cardiol. 2023.

11. Rigotti NA, Kruse GR, Livingstone-Banks J, Hartmann-Boyce J. Treatment of tobacco smoking: a review. JAMA. 2022.

12. Lindson N, Livingstone-Banks J, Butler AR, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2025.

13. Hajek P, Phillips-Waller A, Przulj D, et al. A randomized trial of e-cigarettes versus nicotine-replacement therapy. N Engl J Med. 2019;380:629-637.

14. Auer R, Schoeni A, Humair JP, et al. Electronic nicotine-delivery systems for smoking cessation (ESTxENDS). N Engl J Med. 2024.

15. Rose JJ, Krishnan-Sarin S, Exil VJ, et al. Cardiopulmonary impact of electronic cigarettes and vaping products: AHA Scientific Statement. Circulation. 2023.

16. Osei AD, Mirbolouk M, Orimoloye OA, et al. Association between e-cigarette use and cardiovascular disease among never and current combustible-cigarette smokers. Am J Med. 2019.

17. Hu Y, Zong G, Liu G, et al. Smoking cessation, weight change, type 2 diabetes, and mortality. N Engl J Med. 2018;379:623-632.

18. Lengsfeld S, Burkard T, Meienberg A, et al. Effect of dulaglutide in promoting abstinence during smoking cessation: a randomized controlled trial. EClinicalMedicine. 2023.

19. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med. 2013;368:341-350.

20. Le TTT, Mendez D, Warner KE. The benefits of quitting smoking at different ages. Am J Prev Med. 2024.